Flputnam Investment Management Co. Raises Holdings in Genelux Corporation $GNLX

Flputnam Investment Management Co. lifted its stake in Genelux Corporation (NASDAQ:GNLX) by 708.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 300,290 shares of the company’s stock after purchasing an additional 263,131 shares during the quarter. Flputnam Investment Management Co. owned about 0.80% of Genelux worth $1,261,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Woodward Diversified Capital LLC increased its stake in Genelux by 21.7% during the 2nd quarter. Woodward Diversified Capital LLC now owns 1,778,286 shares of the company’s stock valued at $5,104,000 after purchasing an additional 317,173 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in shares of Genelux during the first quarter valued at $770,000. Heights Capital Management Inc. acquired a new position in shares of Genelux in the 1st quarter valued at $644,000. MAI Capital Management lifted its position in Genelux by 66,161.3% during the 2nd quarter. MAI Capital Management now owns 236,553 shares of the company’s stock worth $679,000 after acquiring an additional 236,196 shares during the period. Finally, Global Retirement Partners LLC acquired a new stake in Genelux during the 2nd quarter worth about $656,000. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Genelux Trading Up 4.0%

Shares of GNLX stock opened at $4.37 on Tuesday. Genelux Corporation has a twelve month low of $1.99 and a twelve month high of $8.53. The stock has a market cap of $166.28 million, a P/E ratio of -4.97 and a beta of 0.07. The stock has a 50 day moving average of $5.64 and a 200 day moving average of $4.28.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. On average, research analysts predict that Genelux Corporation will post -0.88 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director John Thomas sold 10,000 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $5.00, for a total transaction of $50,000.00. Following the sale, the director owned 492,784 shares in the company, valued at approximately $2,463,920. This trade represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 15,990 shares of company stock worth $82,054 in the last quarter. 8.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently weighed in on GNLX shares. Wall Street Zen lowered Genelux from a “hold” rating to a “sell” rating in a report on Saturday. Loop Capital set a $16.00 target price on Genelux in a research report on Tuesday, October 21st. Lake Street Capital assumed coverage on shares of Genelux in a report on Tuesday, October 21st. They issued a “buy” rating and a $16.00 price target on the stock. Maxim Group set a $20.00 price objective on shares of Genelux in a research note on Tuesday, October 21st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Genelux presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.